|
NUCYNTA ER(tapentadol)extended-release tablets for oral
|
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use NUCYNTA® ER safely and effectively. See full prescribing information for NUCYNTA® ER - NUCYNTA® ER (tapentadol ...
These highlights do not include all the information needed to use NUCYNTA® ER safely and effectively. See full prescribing information for NUCYNTA® ER
NUCYNTA® ER (tapentadol) extended-release tablets for oral use
C-II Initial U.S. Approval: 2008
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE- THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
See full prescribing information for complete boxed warning.
-
NUCYNTA ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk before prescribing, and monitor regularly for development of these behaviors or conditions. (5.1)
-
Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Instruct patients to swallow NUCYNTA ER tablets whole to avoid exposure to a potentially fatal dose of tapentadol. (5.2)
-
Accidental ingestion of NUCYNTA ER, especially in children, can result in fatal overdose of tapentadol. (5.2)
-
Prolonged use of NUCYNTA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available (5.3).
-
Instruct patients not to consume alcohol or any products containing alcohol while taking NUCYNTA ER because co-ingestion can result in fatal plasma tapentadol levels. (5.4)
-
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation. (5.4), (7).
RECENT MAJOR CHANGES
|
Boxed Warning |
12/2016 |
|
Warnings and Precautions (5) |
12/2016 |
INDICATIONS AND USAGE
NUCYNTA ER is an opioid agonist indicated for the management of:
-
pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (1)
-
neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (1)
Limitations of Use
-
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve NUCYNTA ER for use in patients for whom alternative treatment options (e.g., non- opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
-
NUCYNTA ER is not indicated as an as-needed (prn) analgesic. (1)
DOSAGE AND ADMINISTRATION
-
To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain. (2.1)
-
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (2.1)
-
Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse. (2.1)
-
Instruct patients to swallow NUCYNTA ER tablets intact, and not to cut, break, chew, crush, or dissolve the tablets (risk of potentially fatal overdose). (2.1, 5.1)
-
Instruct patients to take tablets one at a time, with enough water to ensure complete swallowing immediately after placing in mouth. (2.1)
-
For opioid-naïve and opioid non-tolerant patients, initiate treatment with 50 mg tablet orally twice daily (approximately every 12 hours). See full prescribing information for instructions on conversion, titration, and maintenance of therapy. (2.2, 2.3)
-
Titrate patients with dose increases of 50 mg no more than twice daily every three days. (2.3)
-
Maximum daily dose is 500 mg per day. (2.1)
-
Moderate Hepatic Impairment: Initiate treatment with 50 mg NUCYNTA ER no more than every 24 hours. Do not exceed 100 mg per day. Monitor closely for respiratory and central nervous system depression (2.4)
-
Do not abruptly discontinue NUCYNTA ER in a physically-dependent patient. (2.5)
DOSAGE FORMS AND STRENGTHS
Extended-release tablets: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg (3)
CONTRAINDICATIONS
-
Significant respiratory depression (4)
-
Acute or severe bronchial asthma (4)
-
Known or suspected paralytic ileus (4)
-
Hypersensitivity to tapentadol or to any other ingredients of the product (4)
-
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days. (4)
WARNINGS AND PRECAUTIONS
-
Risk of Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration. (5.1)
-
Serotonin Syndrome: Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue NUCYNTA ER if serotonin syndrome is suspected. (5.6)
-
Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. (5.7)
-
Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of NUCYNTA ER in patients with circulatory shock. (5.8)
-
Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of NUCYNTA ER in patients with impaired consciousness or coma. (5.9)
ADVERSE REACTIONS
The most common (≥10%) adverse reactions were nausea, constipation, dizziness, headache, and somnolence. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Depomed, Inc. at 1-866-458-6389 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with NUCYNTA ER because they may reduce analgesic effect of NUCYNTA ER or precipitate withdrawal symptoms. (5.12, 7)
USE IN SPECIFIC POPULATIONS
-
Pregnancy: Based on animal data, may cause fetal harm. (8.1)
-
Nursing mothers: Nursing is not recommended. (8.2)
-
Severe Hepatic or Renal Impairment: Use not recommended. (8.6, 8.7)
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: 12/2016
FULL PRESCRIBING INFORMATION: CONTENTS*
Table of Contents
1 INDICATIONS AND USAGE
NUCYNTA ER (tapentadol) is indicated for the management of: pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment ...
NUCYNTA ER (tapentadol) is indicated for the management of:
-
pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
-
neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Limitations of Use
-
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1)], reserve NUCYNTA ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
-
NUCYNTA ER is not indicated as an as-needed (prn) analgesic.
2 DOSAGE AND ADMINISTRATION
2.1 Important Dosage and Administration Instructions NUCYNTA ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent ...
2.1 Important Dosage and Administration Instructions
NUCYNTA ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.
| |
